In a rat model, we further confirmed that Met alleviated testosterone-induced pathological changes in BPH tissue, inhibited SOX4 expression, and reduced cell proliferation, EMT process, and fibrosis. Here, SOX4 is linked to benign prostatic hyperplasia.